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Abstract
Alzheimer’s disease (AD) is an age-related neurodegenerative disease and the most common cause of
dementia. The etiology of AD is not entirely clear and despite the increasing knowledge regarding the
pathomechanism, no effective disease-modifying therapy is yet available. Astrocytes earlier presumed
to serve merely supportive roles for the neuronal network, have recently been shown to play an active
role in the synaptic dysfunction, impairment of homeostasis, inflammation as well as excitotoxicity in
relation to AD pathology. This review focuses on the pathomechanism of AD with special attention to
the  role  of  the  astrocytes,  excitotoxicity  and the  alterations  in  the  kynurenine  metabolism in  the
development  of  the  disease.  The  correction  of  the  neuroprotective/neurotoxic  imbalance  in  the
kynurenine pathway may represent a novel target for pharmaceutical interventions in dementia related
to neurodegenerative disorders.
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Introduction
Alzheimer’s  disease  (AD)  is  a  chronic,  progressive,  age-related,  irreversible  neurodegenerative
disease.  It  represents  the most  common cause of dementia  in the  elderly,  affecting some 15-35.6
million people worldwide . Due to the aging of the population, AD represents a serious public health
issue. By 2050, it is expected to affect as many as 13.2 million people in the US, 16.2 million in
Europe  and 115 million worldwide . The clinical features of AD include a gradual impairment of
short-term memory at the beginning of the disease and of long-term memory thereafter and a decrease
in  learning  ability  and  of  language  skills,  accompanied  by  personality  and  behavioral  changes,
ultimately leading to the patient’s inability to perform the activities of daily living and death .  A
familial, genetic form of the disease has been described; however, it represents only a minority of the
total cases of AD . The cause and the mechanisms leading to neurodegeneration in AD have not been
completely elucidated. 
With  regard  to  the  pathologic  alterations,  AD  is  characterized  by  an  excessive  extracellular
accumulation of amyloid-beta (Aβ) in the brain and an intracellular deposition of hyperphosphorylated
tau protein that leads to the formation of neurofibrillary tangles (NFTs). Amyloid plaques are formed
by of aggregated Aβ peptides, whereas NFTs are composed primarily of hyperphosphorylated tau
protein .  There  is  evidence of a  gradual  loss  of neurons and of an altered synaptic  structure and
function in AD, leading to damage to the neuronal network . Pre- and postsynaptic changes, such as an
impairment of neurotransmitter release or an altered expression of certain postsynaptic proteins occur
across the entire brain, but the hippocampus is most critically involved . These alteration results in
brain atrophy, with a significant reduction in size of some brain regions, mainly those involved in the
memory processes, such as hippocampus, frontal cortex and limbic areas . There is also evidence of
activation of the microglia and the astrocytes   in the disease process, and more recently a highly
expression of inflammatory cytokines has been revealed in human AD brain samples . No effective
disease-modifying therapy, capable of preventing the progression of the neurodegenerative process is
yet available. Efforts are continuing is done in order to elucidate the pathomechanisms of the disease
and to find new targets for effective therapeutic interventions. In this respect, there is growing interest
in  understanding  the  mechanisms  of  Aβ  production  and  clearance,  the  alterations  in  cellular
homeostasis, the role of glial cells as well as the role of inflammation and excitotoxicity in AD. This
review focuses on the pathomechanisms of AD, particularly the roles of astrocytes  in the disease
development and aims to reveal connections between amyloid deposition, an astrocyte dysfunction
and excitotoxicity; the latter being an important component in the development of neurodegenerative
diseases. We also discuss the anti-excitotoxic and hence the putative neuroprotective effects of the
neuroactive kynurenines and their potential roles in AD therapy. 
The pathomechanism of AD
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The  cause  of  AD  is  not  yet  known.  Several  hypotheses  exist  attempting  to  explain  the
pathomechanism  of  AD,  these  include  the  cholinergic  deficiency  hypothesis,  the  Aβ  and  tau
hypothesis,  the  inflammation  hypothesis,  the  oxidative  stress  and  mitochondrial  dysfunction
hypothesis, as well as the glutamatergic hypothesis. 
1. The cholinergic deficiency hypothesis
Based on the correlation observed between the loss of cholinergic neurons and the deterioration of
memory in animal models of AD, the cholinergic hypothesis postulates that cholinergic neuronal loss
could be the primary event in AD . This hypothesis is currently falling out of favor, in view of clinical
and experimental results with medications targeting the improvement of cholinergic transmission . 
The α7 nicotinic acetylcholine receptors (α7nAChRs), located presynaptically in the hippocampus and
the cerebral cortex, and have been shown to play a role in the release of different neurotransmitters.
They  enhance  excitatory  glutamatergic  neurotransmission  and  presumably  regulate  synaptic
plasticity . In AD, the function of α7nAChRs is impaired; furthermore, these receptors can bind to the
Aβ oligomers with high affinity . There is recent evidence of a consistent deficiency in the α7AChRs
in patients with AD as well as of an increase in the number astrocytes expressing α7nAChRs. The
latter involved in the production of nitric oxide (NO) and an alteration calcium homeostasis that might
be related to the alterations in the metabolism of the amyloid precursor protein (APP) and to the
inflammation that occurs in AD . 
2. The amyloid and tau hypothesis
The Aβ and tau hypothesis postulates that the development of Aβ or tau protein deposits serve as the
initiating step of AD . The Aβ aggregates are surrounded by dystrophic neurons and reactive glial
cells,  and  the  Aβ peptide  therefore  may presumably be  the  key neurotoxic  agent  that  causes  the
alterations in the neurons and the activation of the glial cells . There is evidence suggesting that it is
not  the  plaques but  the  Aβ oligomers  represent  the  major  cause  of  the  synaptic  dysfunction  and
synaptic failure , and that Aβ causes a mitochondrial dysfunction and impairs the energy homeostasis .
It is presumed that the formation of NFT is a consequence of Aβ aggregation. Tau is a highly soluble
cytoskeleton protein with a role in neuronal transport processes. Hyperphosphorylated and misfolded
tau protein readily aggregates and is toxic to neurons, provoking neuronal dysfunction and apoptosis . 
Aβ is a 37-49 peptide generated from APP. APP plays  a role in the differentiation of the nervous
system, signaling and cell adhesion. There are three APP cleaving enzymes (α-, β- and γ-secretases),
which act differently and lead either to the amyloidogenic or non-amyloidogenic processing of APP
(Fig.  1).  The  action  of  α-  and  γ-secretase  leads  to  soluble  αAPP  (non-amyloidogenic  pathway),
whereas the action of β- and γ-secretase leads to soluble βAPP and the neurotoxic Aβ (amyloidogenic
pathway) . Most of the generated Aβ is Aβ40 and only 10% is represented by Aβ42, which is able to
form aggregates and presumed to be the causative agent of AD . 
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β-Secretase cleaves APP to give the membrane-bound C-terminal fragment β (CTFβ) and βAPP; the
latter is located outside the cell. γ-Secretase cleaves CTFβ to furnish Aβ with an extracellular location
and APP intracellular domain (AICD) with an intracellular location. The α-secretase cleaves APP to
CTFα, which is subsequently cleaved by γ-secretase to form AICD and p3 peptide, both are soluble .
The rate-limiting enzyme of Aβ production is the β-secretase, also named β-site APP cleaving enzyme
(BACE 1 and 2). Therefore, BACE inhibition might be a possible therapeutic option in AD. BACE
and  APP  genes  are  located  on  chromosome  21.  BACE  polymorphism  has  been  shown  to  be
responsible for the sporadic cases of AD that occur in Down’s syndrome . Mutations in the genes
responsible for the non-amyloidogenic processing of APP, such as the γ-secretase subunits presenilin
(PSEN1 and 2), and the ADAM 9, 10 and/or 17 genes, cause increases in Aβ levels and can lead to
early-onset AD .  BACE inhibitors, α-secretase activators, and γ-secretase inhibitors and modulators
are being investigated for their therapeutic effects in AD . 
3. Amyloid metabolism and clearance
Aβ accumulates in the extracellular space within the interstitial fluid (ISF), and forms senile plaques.
This process is presumably facilitated by an altered microenvironment . The extent of the plaques,
however, does not correlate with the severity of cognitive impairment, and it has been shown that it is
not  the  plaques that  are  responsible for the neuronal  damage,  but  rather  the  Aβ oligomers  .  It  is
presumed that Aβ accumulates in the intracellular compartment due to amyloidogenic APP processing
and to an ineffective neuronal catabolism of Aβ . 
4. Amyloid clearance and some factors influencing it (Fig. 2)
Several mechanisms play a role in the intracellular clearance of Aβ, for instance the Rab GTPase
family members, and lysosomal enzymes such as the cathepsins, or the newly described neprilysin
(NEP). Their altered function leads to the intracellular accumulation of Aβ and eventually cell death .
Another  source  of  intracellular  Aβ  is  its  reuptake  from the  extracellular  space.  The  intracellular
accumulation of Aβ is presumed to be responsible for the initial injury of the synapses and neurites in
the early stages of AD . The glial cells play a fundamental role in the clearance of Aβ from the brain
parenchyma.  Besides  they  are  phagocytic  activity,  they  are  also  the  source  of  apolipoprotein  E
(ApoE), the main chaperon of Aβ in the central nervous system. Among the isoforms described, the
ApoEε4 variant is one of the most important risk factors for AD . Among the secondary chaperons,
ApoJ, transthyretin and alfa2-macroglobulin play roles in the clearance Aβ. The Aβ is exported from
the brain interstitial fluid (ISF) to the blood by specialized carriers through the blood-brain barrier
(BBB), and to a lesser extent through the choroid plexus-cerebrospinal fluid (CSF) and the CSF-blood
barrier at the Virchow-Robin spaces. The carriers involved in this transport include the low-density
lipoprotein receptor-related proteins (LRP1 and 2) and the ATP-binding cassette. Genetic variations of
these transporters influence disease progression in AD. Aβ is eliminated in the liver and to a lesser
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extent in the kidney.  Among the nuclear receptors, the peroxisomal proliferator-activated receptors
(PPARs) have a relevant role in the brain Aβ clearance and it has been shown in experimental models
that the activation of PPARs has a beneficial effect on the pathology of AD and the mitochondrial
dysfunction . 
It is presumed that the deposited Aβ peptides evoke neuronal dysfunction and neurodegeneration, on
the one hand via toxic dendritic and synaptic injury and, on the other hand, through the activation of
microglial cells and astrocytes . 
It has been revealed that the Aβ-induced neuritic damage in AD is mediated by glycogen synthase
kinase (GSK-3). This enzyme also regulates tau protein, it promotes tau phosphorylation, and can
thereby cause destabilization of the microtubule network. Furthermore, GSK-3 interacts with the  N-
methyl-D-aspartate receptors (NMDARs) and hence the glutamatergic system. Additionally, inhibitors
of GSK-3 interfere with the cleavage of APP and block the production and accumulation of Aβ .
Despite the sound evidence of the role of Aβ in the pathomechanism of AD, reduction of the Aβ levels
in the brain has been shown in clinical trials, not to improve the cognitive function in AD patients,
even though there  was evidence indicating the clearance of  Aβ plaques.  This  suggests  that  other
factors might also be involved in the pathogenesis of AD .
5. The role of inflammation in the pathomechanism of AD
Chronic  inflammation  contributes  to  the  pathogenesis  of  neurodegenerative  diseases  and  is  an
established feature of AD as well . In contrast, hypotheses exist proposing that neuroinflammation
might have a protective role and that microglial activation may diminish the pathologic changes by
releasing immune suppressing and neurotrophic agents . 
The microglia have a phagocytic capacity and are activated by a variety of inflammatory processes
and diseases affecting the central nervous system (CNS). Activated microglia express cell  surface
molecules such as cytokine and chemokine receptors, CD11b, CD11c, CD14, MHC molecules, Fc
receptors  and  scavenger  receptors,  they  also  have  pattern  recognition  receptors  of  the  Toll-like
receptor  (TLR)-type  and  acting  as  antigen-presenting  cells  (APCs).  Aβ  activates  microglia  and
astrocytes  through the TLRs as well ,  which induces a signaling cascade that further involves the
activation of transcription factors (e.g. NF-kappaB, AP-1) . During the microglial neuroinflammatory
response, inflammatory mediators, neurotoxic cytokines, proinflammatory chemokines and reactive
oxygen species (ROS) are released . Some of these factors induce the chemotaxis of astrocytes around
the plaques . As a result, activated microglial cells recruit astrocytes and induce their proliferation .
Astrocytes  have  been  shown  to  enhance  the  neuroinflammatory  response.  The  aim  of  glial  cell
activation is the clearance of Aβ deposition; however, the chronic inflammatory conditions lead to
damage to the surrounding neurons and promote further amyloidogenesis, as shown in animal models .
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Notably,  an elevation of inflammatory markers can be detected in the serum and CSF before any
increase in Aβ or hyperphosphorylated tau could be noted . Accordingly, the plasma levels of certain
the inflammatory markers, such as IL-6, TNF alfa, IL-10 and IL-13, have been shown to correlate
inversely with the whole brain volume, the entorhinal cortex volume and the ventricular volume in AD
.
A body of evidence from epidemiological studies suggests that medication with non-steroidal anti-
inflammatory (NSAIDs) reduces the risk of development of AD and can delay the onset and reduce
the severity of AD symptoms, thereby supporting the role of inflammation in the pathomechanism of
AD .  It  has been shown that  NSAIDs exert  their  protective role by modulating the activity of γ-
secretase and by altering the β-sheet conformation of Aβ and hence its ability to aggregate . Despite
the established role of inflammation in the pathology of AD, clinical trials with NSAIDs produced
negative results . It has been suggested that these medications might be beneficial in the very early
stages of the disease process .
There is recent interesting evidence that a high-fat diet is a significant risk factor for the development
of AD and that long-chain fatty acids such as palmitic acid or lauric acid, stimulate inflammatory
markers and processes involved in AD and modulate the amyloid processing. It is presumed that a
high-fat  diet  increases the uptake of fatty acids from the plasma to the brain,  predominantly into
astrocytes  located  in  the  vicinity  of  the  BBB .  In  experimental  models,  an  increase  in  BACE 1
expression has been observed in astrocytes exposed to palmitic acid .
6.  Oxidative stress and the role of a mitochondrial dysfunction in AD 
APP and Aβ react with mitochondrial components and lead to a mitochondrial dysfunction, which
increases the synaptic damage  and causes neuron apoptosis .  Mitochondrial  dysfunction results  in
impaired  ATP  production  and  increased  oxidative  stress,  which  further  enhances  inflammatory
processes. It has been shown that ApoE4 impairs mitochondrial trafficking and function, and promotes
apoptosis .
7. The glutamatergic hypothesis  
The NMDARs play an important  role  in learning and memory functions  as well  as  in regulating
synaptic plasticity; however, an overactivation of these receptors result in an excess calcium influx
and induces neuronal damage and eventually neuronal death . The NMDARs are activated by the Aβ
oligomers and they mediate the effects of tau protein in AD . Overactivation of the NMDARs induces
the cleavage of the enzyme GSK-3 by activated calpain . On the other hand, a GSK-3 inhibitor exerts
protective  action  against  NMDAR-induced  excitotoxicity  by  inducing  a  downregulation  of  the
NMDARs, an effect that is compromised in the presence of Aβ. It is presumed that altered GSK-3
signaling may be a pathophysiological mechanism in AD . 
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Astrocytes 
The astrocytes, the most abundant glial cells in the CNS, play an essential role in maintaining the brain
structure and function. There is an emerging concept of glial cells contributing to the pathogenesis of
neurological diseases due to their critical function in maintaining brain homeostasis (glio-centric view)
.  Indeed,  astrocytes  can  contribute  to  neuropathological  processes  either  by  loss  or  pathological
modification of their function (astroglial asthenia and astrocytopathology,  respectively),  or through
astroglial reactivity. A central role of astrocytes in the pathomechanism of certain diseases, such as
hepatic encephalopathy has been already been documented,  where a reduced glutamate uptake, an
enhanced glutamine  production,  and a  reduced K+ buffering have been described.  Though not  so
clearly  unraveled,  the  astrocytes  play  a  fundamental  role  in  the  development  of  other
neurodegenerative disorders as well, such as AD . The following sections further detail the functions
of astrocytes and their impairments in AD (Fig. 3). 
1. Maintenance of brain homeostasis
The astrocytes maintain the fluid, ion, neurotransmitter and pH balances (homeostasis) in the synaptic
space. Experimental studies demonstrated that water exchange between the brain, the blood and the
different brain compartments is regulated by astrocytes through aquaporin 4 (AQP4). Importantly, an
altered AQP4 expression has been revealed in the astrocytes  of AD patients and in AD models  .
During repolarization, when the extracellular potassium concentration increases, astrocytes take up the
excess potassium through a potassium channel and are able to release it via gap junctions, thereby
stabilizing the neuronal activity .
Ca2+ signaling in the astrocytes is essential for neuronal communication. It modulates neuronal activity
and survival, and is involved in neuronal death following ischemia . Increases in intracellular calcium
concentrations have been observed in astrocytes at the presence of relatively low Aβ concentrations.
This has significance in intercellular communication; however, there is no propagation of an action
potential  along  their  processes.  In  the  astrocytes,  the  presence  of  Aβ  induces  an  increase  in
intracellular calcium concentrations, which can upregulate glial fibrillary acidic protein (GFAP) and
S100β, stimulate the signaling pathways of BACE 1 expression, promote the formation of ROS, lead
to cell dysfunction and ultimately cell death .
The extracellular pH is regulated by the transport of H+ with a Na+/H+ exchanger and through the
lactate and glutamate transporters in astrocytic membranes . 
2. Neurotransmitter regulation
Astrocytes perform the reuptake of neurotransmitters including glutamate. Within the astrocytes these
transmitters are metabolized to precursors, which can reenter into neurons after astrocytic release and
can  be  reconverted  into  active  neurotransmitters.  Furthermore,  in  response  to  certain  changes  in
synaptic activity, the astrocytes are able to release purines and glutamate. These observations led to
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the “tripartite synapse hypothesis”, according to which astrocytes constitute a functional synapse with
the neuronal synaptic elements, and directly interact with them during synaptic activity . There is
scientific  evidence  that  in  addition  to  an  intracellular  elevation  of  calcium  levels,  inflammatory
molecules  are  also necessary for  astrocytic  gliotransmitter  release.  Astrocytes  are presumed to be
activated in  neurodegenerative diseases  during an early inflammatory  process  .  The activation of
astrocytes  is  characterized  by  proliferative  and  morphologic  alterations  and  the  upregulation  of
GFAP . 
3. Role in inflammatory processes 
There are increases in the number, the size and the motility of astrocytes surrounding amyloid plaques.
Activated  astrocytes  express  pro-inflammatory  molecules  and  thereby  participate  in
neuroinflammation  and  neurodegeneration.  However,  astrocytes  can  also  provide  neuroprotection
through a release of neurotrophic factors. Molecules secreted by activated astrocytes include S100β,
chemokines and cytokines such as IL-1β, IL-6, TNFα and TGFβ . The responses of the astrocytes to
the progression of AD have not yet been completely unraveled ; however, substances released in result
of cell  death have been shown to activate both microglia and astrocytes,  through the receptor for
advanced  glycation  end-products  .  Figure  4  presents  the  role  of  activated  astrocytes  in  the
inflammatory processes in AD pathomechanism. 
4. Signal transmission and synaptic connectivity 
Besides providing metabolic and trophic support to the neurons, the astrocytes modulate information
processing, synaptic transmission and signal transmission throughout the CNS, and regulate neural and
synaptic  plasticity.  In  this  respect,  the  astrocytes  secrete  neural  growth factors,  such as  the  glial-
derived  growth  factor  (GDNF)  and  the  brain-derived  neurotrophic  factor  (BDNF).  It  has  been
demonstrated that the astrocytic function is crucial for memory formation .
The astrocytes are essential for synapse formation during astrogliogenesis, for synapse maturation and
for the maintenance of synaptic connectivity throughout life. Increases in synaptic activity and in the
number  of  synapses  are  mediated  by  thrombospondin,  a  matrix-associated  protein  generated  by
astrocytes . The astroglial membranes are very thin structures that cover synapses. Their perisynaptic
processes are devoid of organelles and neurotransmitter vesicles, but contain molecules responsible for
the transport of  ions,  neurotransmitters,  glutamine and neurotransmitter  receptors.  These processes
provide  morphological  plasticity  and can  change  the  synaptic  coverage  dynamically,  and  thereby
regulate the neurotransmitter concentration and synaptic connectivity . In AD, signs of morphological
atrophy of the astrocytes have been demonstrated. These morphological alterations may result in an
insufficient  synaptic  coverage,  which  might  impair  the  synaptic  connectivity  and  contribute  to
neuronal death . In AD animal models, these morphological changes were shown very early in the
most vulnerable brain regions, such as the entorhinal and prefrontal cortices . 
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5. Regulation of blood flow
Through the production of arachidonic acid, prostaglandins and NO, which increase or decrease the
blood vessel diameter, astrocytes can regulate the local CNS blood flow in response to changes in
neuronal  activity  .  Through  paravascular  processes,  the  astrocytes  ensheath  97%  of  the  CNS
vasculature  and leave only small clefts between the blood vessels and the endfeet, thereby allowing
the CSF from the subarachnoid space to flow along the blood vessels  throughout  the  brain.  This
phenomenon was revealed by dynamic  two-photon and contrast-enhanced MR imaging .  In these
paravascular spaces, its content of the CSF can exchange with the ISF of the brain parenchyma. The
clearance of interstitial  substances,  including Aβ, is possible along the paravenous spaces .  These
paravascular CSF channels together with astrocytes compose the glymphatic system in the CNS . The
change of substances through this system is facilitated by arterial pulsatility and is most active during
sleep . Exchange of water within this system is supported by astrocytes as well via the expression of
the AQP4 water channels .
Earlier studies indicate that a cerebrovascular dysregulation and damage to the BBB occur in AD, and
that the risk of sporadic AD is increased by transient hypoxic or ischemic attacks, silent infarcts and
stroke  episodes  .  A  connection  has  been  discovered  between  AD  and  cardiovascular  disease,
suggesting that sporadic AD might in fact be a vascular disease characterized by an impaired neuronal
perfusion and the accumulation of toxic  metabolic  products  due to an altered permeability of the
BBB . In this respect, areas of hypoperfusion and changes in cerebral blood flow have been revealed
by imaging studies (PET and CT scans, respectively) in the parahippocampal gyrus, the frontal and the
temporal cortex as well as in the hippocampus in AD patients . Amyloid angiopathy, present in up to
90% of AD patients , is presumed to be a result of a failure to eliminate Aβ from the cerebral blood
vessels  .  Astrocytes  together  with  the  neurons,  the  pericytes  and  the  microglia  constitute  the
neurovascular unit (NVU), which has roles in maintaining the permeability of the BBB, the cerebral
blood flow and hence the brain homeostasis. The astrocytic endfeet form a barrier between the neurons
and the blood vessels and control the local blood flow in accordance with metabolic demands .
6. Role of the astrocytic glycolytic metabolism in AD
The astrocytes are the major glucose consumers in the brain, responsible for the utilization of about
85% of  the  total  glucose,  whereas  the  neurons consume  only small  amounts  .  This  difference is
explained by the higher expression of the glycolysis-promoting enzyme system 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase  (PFKFB3)  in  the  astrocytes  than  in  the  neurons.  The  astrocytes
present  a  low activity of  the  ubiquitylation  enzyme  APC/C-Cdh1,  which regulates  the  activity of
PFKFB3.  The  result  is  a  higher  rate  of  glycolysis  in  the  astrocytes  than  in  the  neurons  and the
sensitivity of neurons to depleted energy states. With aging, the uptake and the metabolism of glucose
decline and a decrease in the rate of glycolysis occurs in astrocytes . This metabolic change can be an
early phenomenon in the development of AD . Animal models of AD and the post-mortem analysis of
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AD patient brains demonstrated a down-regulation of the genes related to the glycolytic pathway . In
AD patients, changes in activity of the glycolytic enzymes have been observed, with a reduced activity
of glucose-6-phosphate in the hippocampus and an increased activity of lactate dehydrogenase in the
temporal  and  frontal  cortices  .  The  alterations  in  glucose  metabolism  in  AD  are  linked  to  Aβ
aggregation, internalization and an ineffective astrocytic clearance. The intracellular accumulation of
Aβ  impairs  the  astrocytic  glucose  metabolism  and  leads  to  decreased  glutathione  and  lactate
production, which increases the vulnerability of the neighboring neurons . The changes in the activity
of glycolytic enzymes were observed to correlate with an increased GFAP expression in the astrocytes
and with the spatial distribution of Aβ deposits in the human brain . 
Astrocytes and amyloid deposition
There is an interconnection between reactive astrogliosis and amyloid deposition. The formation of Aβ
is  related to  reactive astroglia   while  on the other  hand,  Aβ activates  the  astrocytes  and induces
morphologic and functional alterations within them. These include an increase in GFAP, S100β factor
and IL1β . Activated astrocytes are present in animal models of AD and in the brains of AD patients
and,  as  outlined  above,  in  some  studies  reactive  gliosis  has  been  shown  to  even  precede  other
morphological changes characteristic of AD or to be an early phenomenon in AD . It has also been
suggested, that the progression of amyloid deposition is different from that of astrocytosis and that
gliosis might continuously contribute to the ongoing neurodegeneration . 
The  reactive  astroglial  change  in  AD  is  predominantly  focal  in  distribution,  and  the  astrocytes
surrounding the amyloid plaques are suggested to play several key roles in AD pathology, including
amyloid uptake and amyloid clearance. Indeed, an overexpression of BACE 1 and an accumulation of
intracellular Aβ have been documented in the astrocytes in AD . It has been shown more recently that
an overexpression of BACE 1 occurs in reactive astrocytes located around the amyloid plaques, as a
result  of  the  action  of  proinflammatory  cytokines,  and  the  astrocytes  may  therefore  become  an
important source of Aβ in AD . Subsequently a vicious circle may develop, in which the astrocytes
around  the  amyloid  plaques  release  proinflammatory  molecules  and  cytokines,  such  as  IFNγ,
TNFαand IL-1β, which then stimulate other astrocytes, activate BACE 1 activity and lead to further
Aβ production. The accumulations of Aβ42 species were demonstrated to correlate with the extent of
local histopathological changes. The astrocytes preferably take up oligomeric Aβ. The uptake of Aβ42
were shown to be more pronounced during the early stages of the disease, but no impairment of the
amyloid uptake by astrocytes could be proved in AD . Amyloid uptake is influenced by the amyloid
plaque-associated proteins, such as α1-antichymotrypsin (ACT-1), ApoJ and ApoE, by the enzyme
lipoprotein lipase and via the overexpression of the low-density lipoprotein receptor. Furthermore,
astrocytes  have been shown to overexpress ACT-1, which presumably inhibits Aβ breakdown and
might induce the hyperphosphorylation of tau protein . 
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Notably, astrocytes are capable not only of the uptake, but also of the clearance of Aβ from the brain
into the perivascular space and of the degradation of Aβ  (Fig. 3). The degradation of the internalized
amyloid occurs in the lysosomal pathway. Three enzymes are responsible for the degradation of Aβ:
NEP,  insulin-degrading enzyme  and matrix  metalloproteinase-9 (MMP-9)  .  NEP is regulated in a
feedback  manner  directed  by  AICD released  during  amyloid  cleavage,  but  it  is  only  capable  of
degrading  soluble  forms  of  Aβ.  The  insoluble  forms  are  degraded  by  glial  cells  and  MPPs  .
Angiotensin-converting enzyme-1 and endothelin-converting enzyme-2 inhibit NEP, thereby reducing
Aβ clearance  .  The  upregulation  of  NEP in  normal  astrocytes  and in  astrocytes  surrounding the
amyloid deposits suggests a neuroprotective role of astrogliosis. Astrocytes derived from AD patients,
however, show no increases in NEP, suggesting a functional deficit of astrocytes in AD . 
Excitotoxicity
Glutamate, the major excitatory neurotransmitter in the CNS, is involved in synaptic transmission and
plasticity,  neuronal  growth,  learning  and  memory.  Glutamate  excitotoxicity  has  been  shown  to
contribute  to  neuronal  death  in  ischemia,  traumatic  brain  injury  and  several  neurodegenerative
diseases,  including  AD.  Astrocytes  have  an  essential  role  in  maintaining  extracellular  glutamate
concentration below a toxic level, by the use of the glutamate-glutamine cycle and excitatory amino
acid transporters (EAAT). It has been suggested that cytokines are responsible for the changes induced
in the glutamine-glutamate cycle in AD. In the presence of TNFα, EAAT1 is downregulated and the
expression of glutamine synthetase (GS) is reduced. This results in a reduction in glutamate uptake
together with a reduction in glutamine release by astrocytes; therefore astrocytes become unable to
protect neurons from glutamate excitotoxicity . 
1. Role of the glial cells in excitotoxicity. Glutamate synthesis
Activated microglia  are capable of inducing excitotoxicity and neurodegeneration by an excessive
release of glutamate . The astrocytes are essential for glutamatergic and gamma-aminobutyric acid
(GABA)-ergic  neurotransmission,  and  the  glutamine-glutamate/GABA  cycle  requires  interactions
between the neurons and the astrocytes . The syntheses of these neurotransmitters from glucose take
place  within  the  astrocytes,  since  neurons  lack  the  necessary  enzymatic  apparatus.  As  such,  the
astrocytes  provide  the  neurotransmitter  glutamine  for  neurons  in  the  glutamine-glutamate/GABA
cycle. On the other hand, glutamate from the extracellular space is partly taken up by the astrocytes,
converted to glutamine and subsequently returned to the neurons. Within the neurons, glutamine is
further metabolized to form GABA and glutamate  (Fig. 5). 
2. Glutamate synthesis
Within the astrocytes, glucose is transformed glycolytically into pyruvate. Pyruvate is degraded by
pyruvate dehydrogenase to form acetyl coenzyme A (CoA). This condenses with oxaloacetate to form
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citrate, which is a constituent of the tricarboxylic acid (TCA) cycle. Two molecules of pyruvate are
necessary to form a de novo molecule of citric acid. During one TCA cycle, citrate loses carbon and is
transformed  into  oxaloacetate,  which  condenses  again  with  acetyl-CoA  for  energy  production.
Pyruvate can also be converted in the astrocytes to a de novo oxaloacetate by the action of pyruvate
carboxylase,  an  enzyme  not  present  in  the  neurons.  Through  this  production  of  de  novo citrate
molecules, the TCA intermediate α-ketoglutarate becomes available for glutamate synthesis. It is not
clear whether this process is catalyzed by glutamate dehydrogenase or by aspartate aminotransferase.
The complex pathway of glutamate synthesis has been suggested to be directly coupled to the process
of the astrocytic degradation of glutamate and GABA . 
In the astrocytes, glutamate is converted into glutamine by glutamine synthetase (GS). Glutamine is
released from the astrocytes through the system N 1 (SN1) transporter. From the extracellular space,
glutamine enters the neurons through the system A transporter 1 and 2 (SAT1 and SAT2) transporters.
Glutamine  is  then  converted  by  phosphatase-activated  glutaminase  (PAG)  into  glutamate  at  the
membrane of neuronal mitochondria . Subsequently, glutamate packed into vesicles via the vesicular
glutamate transporters (VGLUTs). A small amount of the neurotransmitters released by the neurons
are returned to the neurons themselves by a reuptake mechanism; however, the majority enters the
astrocyte through transporters, where they are re-converted to glutamine. Recent research suggests that
about  15% of the glutamate  released from the neurons is  oxidatively degraded in the astrocytes  .
Furthermore, it has been shown that the glutamine can move from one astrocyte to an other through a
functional syncytium, and astrocytes might therefore be able to supply even neurons situated at some
distance with glutamine, presumably in a regulated process . 
One of the essential roles of the astrocytes is to maintain sufficiently low levels of glutamate in the
extracellular space, thereby preventing excitotoxic neuronal injury. The uptake of glutamate into the
astrocytes is achieved by two glutamate transporters: glutamate aspartate transporter (GLAST) (also
known as excitatory amino-acid transporter 1 (EAAT1)) and glutamate transporter-1 (GLT-1) (also
known  as  excitatory  amino-acid  transporter  2  (EAAT2)).  The  transport  of  glutamate  is  energy-
dependent and requires the uptake of 3 Na+ and one H+ and the efflux of K+. Mutations of the genes
encoding these transporters lead to excitotoxicity and neurodegeneration, as demonstrated in animal
models . 
Astrocytes  are  a  source  of  glutathione,  superoxide  dismutase  and  ascorbate,  and  thereby  exert
antioxidant properties, which act in order to prevent excitotoxic injury . Astrocytes may also possess
neuroprotective properties through the production of neurotrophic factors, as mentioned above (i.e.
BDNF, GDNF and insulin-like growth factor (ILGF)) . 
Experimental models of AD revealed a decrease in glutamate uptake and a decreased expression of
EAATs , which changes that have been linked to the deposition of Aβ . EAAT gene transcription has
been demonstrated in experimental models to be modulated by the YY1 transcription factor under both
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physiological  and  pathological  conditions,  and  targeting  such  signaling  pathways  could  offer
therapeutic benefits in AD . 
3. Excitotoxicity in AD - excitotoxins and amyloid
The  neuropathological  staging  system  introduced  by  Braak  suggest  that  the  entorhinal  cortex  is
involved in the early progression of AD . The entorhinal cortex receives afferents from the fourth
cortical layer, the association cortex, the hippocampus and other parts of the limbic cortex, and gives
projections to the hippocampus and the association cortex. These afferents and some of the efferent of
the entorhinal cortex, such as the perforant pathway, which originates predominantly from the second
entorhinal layer and projects to the hippocampus, are glutamatergic. In preclinical and in mild cases of
AD, a reduction in the number of neurons in the second and fourth layers of the entorhinal cortex has
been detected . The conversion from the stage of mild cognitive impairment to dementia might be
characterized by a synaptic loss in the outer molecular layer of the dentate gyrus . Synaptic loss has
been revealed to be the strongest predictive factor for cognitive decline in AD, as indicated by a delay
in memory recall or a decline in the results of the Mini-Mental State Examination test. In the advanced
stages of the disease, a severe neuronal loss occurs in the neocortical association areas . Molecular
markers  of  glutamatergic  synaptic  dysfunction  can  be  detected  even  in  the  early  stages  of  AD.
Decreases  in  the  expression  of  VGLUT1  and  VGLUT2  and of  synaptophysin   as  well  as  a  co-
localization of Aβ with VGLUT1 and 2 transporters in the presynaptic terminals were observed . The
dysfunction of the glutamatergic network is presumably due to the neurotoxic Aβ peptide and tau
protein. Aβ influences the glutamatergic neurotransmission in several ways. Aβ aggregates can induce
tau  hyperphosphorylation  and aggregation,  which  results  in  further  neurotoxicity  .  Aβ  deposition
affects the glutamatergic synaptic vesicular pool and impairs neurotransmitter release and synaptic
transmission.  The  postsynaptic  ionotropic  glutamate  receptors  include  the  α-amino-3-hydroxy-5-
methyl-4-isoxazole  propionic  acid  (AMPA)  receptors,  the  NMDARs,  and  the  G  protein-coupled
metabotropic glutamate receptors, which can be divided into three groups according to their functions .
Aβ exerts its neurotoxic effects predominantly on the NMDARs, stimulation of which enhances Aβ
production.  The NMDAR is  a  tetramer  composed of  two glycine-binding units  that  form the ion
channel  and  two  glutamate-binding  subunits  with  a  modulating  role.  NMDARs  that  contain  the
phosphorylated  GluN2B  subunit  are  predominantly  located  extrasynaptically  .  Experimental  data
suggest  that  stimulation  of  the  NMDARs  at  the  extrasynaptic  site  is  neurotoxic,  whereas  their
activation at the synaptic site promotes cell survival . Notably, Aβ activates Fyn kinase that causes
increased  phosphorylation  of  the  GluN2B subunit,  which  expands the  spectrum of  the  NMDAR-
mediated  toxic  effects  of  Aβ  on  neurons.  Besides  these  morphological  changes  induced  by  Aβ
oligomers in the synaptic transmission, functional changes have also been documented. Aβ causes
synaptic  dysfunction  by  impairing  the  long-term  potentiation  (LTP;  which  follows  brief,  high-
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frequency  stimulation)  and  by  potentiating  the  long-term  depression  (LTD;  which  follows  low-
frequency stimulation) . 
High-frequency stimulation  of  presynaptic  glutamatergic  neurons  induces  an  increased  release  of
glutamate  in  the  synaptic  cleft.  First,  the  AMPARs and the metabotropic  glutamate  receptors  are
stimulated. Their sustained activation leads to activation of the NMDARs. The activation of NMDARs
containing  the  GluN2A subunit  evokes  an  increase  in  the  postsynaptic  Ca2+ concentration,  which
subsequently initiates a cascade of events involved in LTP induction. A decreased stimulation of the
glutamatergic synapse  leads  to the  internalization of  the synaptic  NMDARs and activation of the
extrasynaptic  NMDARs  that  contain  GluN2B  subunits,  and  induces  a  weaker  increase  in  the
postsynaptic Ca2+ concentration, a phenomenon referred to as LTD. In physiological conditions, this
phenomenon  is  associated with  the  synapse  remodeling,  whereas  in  pathological  conditions,  with
synaptic failure . Activation of the GluN2B subunits can induce apoptosis via caspase-8 and caspase-3,
and might be responsible for synaptic dysfunction and neuronal death in AD . 
Aβ also induces internalization of the AMPARs, an effect that requires the metabotropic activation of
the NMDARs . A scaffolding protein that binds to the GluN2B subunit connects the NMDARs to NO
synthase and may have an important  role  in excitotoxicity through excessive production of  NO .
GluN2B-mediated glutamatergic neurotransmission is involved in the neurotoxic effects exerted by
tau protein on the synaptic function . As described above, Aβ causes an impairment of the astrocyte
function,  downregulating  their  glutamate  uptake  capacity.  A  revision  of  the  importance  of  the
kynurenine pathway (KP) in the elimination of glutamate excitoxicity in AD should be considered.
Kynurenines and their potential roles in AD
Since  numerous  data  sources  suggest  that  the  KP  is  involved  in  the  pathogenesis  of  various
neurological disorders (pain syndromes, stroke and epilepsy ), special emphasis is placed on reviewing
its role in neurodegenerative processes, such as Huntington’s disease (HD) , Parkinson’s disease (PD)
and AD . 
1. Metabolism, receptors and main effects of kynurenines
The KP is expressed in astrocytes, neurons, macrophages, and glial, endothelial and dendritic cells,
and the largest amounts of kynurenine metabolites are utilized in the CNS . The KP is the major route
of  the  catabolism of  tryptophan  (Trp).  Approximately  95% of  this  essential  amino  acid  may  be
converted to “kynurenines” by special enzymes (Trp and/or indoleamine 2,3-dioxygenases; i.e. TDO
and/or  IDO-1,  IDO-2)  .  This  conversion  results  in  L-kynurenine  (L-KYN),  via  the  N-
formylkynurenine transition product in the plasma. L-KYN is synthesized in the brain at the rate of
0.29 nmol/g/h  and serves as a key molecule between the neurotoxic and neuroprotective directions of
the  pathway.  Quinolinic  acid  (pyridine-2,3-dicarboxylic  acid,  QUIN),  a  neurotoxic  compound  is
produced from L-KYN in the microglia cells, catalyzed by kynurenine 3-monooxygenase (KMO), via
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additional  toxic  metabolites  (3-hydroxykynurenine,  3-HK  and  3-hydroxyanthranilic  acid).  These
agents can generate toxic free radicals, oxidative stress, lipid peroxidation and glutamate excitotoxicity
through activation of the essential amino-acid receptors (EAARs).  In contrast, the characteristically
neuroprotective  kynurenic  acid  (4-hydroxyquinoline-2-carboxylic  acid;  KYNA)  is  formed  directly
from L-KYN in the astrocytes, catalyzed by kynurenine aminotransferases (KATs)   (Fig. 6) and is an
endogenous inhibitor of the EAARs .
KYNA is primarily a nonselective antagonist of the strychnine-insensitive glycine-binding site of the
NMDARs . Furthermore, it can noncompetitively block the nicotinergic processes at the α7nAChRs,
and it has the ability to inhibit  the effects of AMPARs and kainate receptors only in mM doses . It
takes part in neuronal and glial glutamatergic neurotransmission, intracellular Ca2+ concentration and
mitochondrial membrane damage-induced neuronal cell death  and neurodegeneration in the CNS .
Most of the effects of KYNA (neuroprotective, antinociceptive and anti-inflammatory) are explained
by inhibition of the EAARs, but other interactional partners have recently been also identified . KYNA
is able to interact with the orphan G protein-coupled receptor 35 (GPR35), which is expressed in the
neurons and glial cells (in the brain and dorsal root ganglia) and in the macrophages and monocytes
(in the immune system) . As an agonist, KYNA Presumably activates the GPR35Rs, which decreases
the  level  of  cyclic  adenosine  monophosphate,  the  intracellular  Ca2+  concentration,  and  hence  the
release of glutamate and proinflammatory mediators . KYNA can also act as an agonist on the aryl
hydrocarbon receptor, which is essential in fundamental cell biology, maturation of the immune and
nervous systems and carcinogenesis . Certain results concerning the relationship between the opioid
and the kynurenine systems , suggest that the opioid receptors may also be a targets for kynurenine
metabolites.
In healthy subjects under normal conditions the concentration of KYNA is nanomolar in the brain and
micromolar in the blood plasma , but significant changes have been observed in the concentrations of
kynurenine metabolites in different diseases. Research has revealed that a shift in the QUIN/KYNA
rate  toward  the  formation  of  toxic  QUIN  induces  epileptic  seizures  and  HD-like  symptoms  via
neurotoxicity and lipid peroxidation . 
2. Roles of kynurenines in neurodegenerative disorders
2.1 Huntington’s disease
Relative decreases in the level of KYNA and a reduced activity of KAT have been demonstrated in the
striatum of HD patients . Elevated concentrations of 3-HK can also contribute to the formation of
neurodegenerative diseases such as HD . A preclinical rat model of HD revealed a severe reduction in
KAT-I  immunopositivity  in  the  striatum  after  chronic  (3-nitropropionic  acid)  treatment  .  The
intrastriatal administration of QUIN, a possible endogenous neurotoxin in HD, provoked increased
neuronal  vulnerability  in  KAT-II-deficient  mice  ,  which  suggests  the  importance  of  KYNA  in
controlling the effects of QUIN . Zádori and co-workers demonstrated that the systemic administration
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of a novel KYNA derivative prolonged the survival of the animals, ameliorated the hypolocomotion
and prevented weight-loss and the atrophy of the striatal neurons in a transgenic mouse model of HD .
These data illustrated that alterations in the KP can contribute to the development of HD and increased
KYNA concentration may prove protective against neurodegeneration . 
2.2 Parkinson’s disease
There is evidence that PD is accompanied by a shift in the KP . Ogawa and co-workers found that the
concentrations of KYNA were decreased in the frontal cortex, putamen and pars compacta of the
substantia  nigra  of  patients  with  PD, whereas  the  3-HK  levels  were  increased  in  the  putamen,
indicating oxidative damage . It emerged from animal models of PD that mitochondrial neurotoxins
cause decreased KAT immunoreactivity and subsequently a diminished KYNA levels in the brain
affected by PD . Attenuated KAT-1 and KAT-2 activity and KYNA levels that were measured in the
blood plasma of PD patients, but increased expressions of both these enzyme isoforms and the KYNA
levels were observed in the red blood cells, suggesting a protective response against neurotoxic effects
. A clinical study revealed increased 3-HK levels in the cerebrospinal fluid of PD patients, confirming
the relevance of the KP in mechanisms of neurodegeneration .
2.3 Alzheimer's disease
An  ever  increasing  amount  of  evidence  indicates  that  an  altered  kynurenine  metabolism  is  also
implicated in the pathology of AD, but the mechanisms have not been identified in detail, and the
influence  of  the  KP  in  the  development  of  the  disease  is  rather  controversial.  There  are  two
conceptions as concerns the role of an elevated KYNA levels in AD:  it may be a causative factor in
the development of AD or it may take part in a compensatory repair mechanism.
Kynurenines as provoking/damaging or compensatory/repair factors of AD
Widner and co-workers found that the concentration of Trp still tended to be lower in AD patients due
to the enhanced degradation of Trp reflecting the significantly increased KYN/Trp ratio . Although
KYNA inhibits  the  excessive  release  of  glutamate  during  excitotoxicity,  massive  increase  in  the
KYNA concentration in healthy subjects can trigger neuronal death. These processes may take place
in AD, where the level of L-KYN rises in the brain and the plasma resulting in an elevated systemic
KYNA content  .  KYNA-induced EAAR inhibition may be responsible  for  the  impaired  learning,
memory and cognition in  AD patients.  An increased serum KYN/Trp  ratio  was  observed in  AD
patients, indicating an enhanced IDO activity,  which may be associated with the reduced cognitive
performance . An elevated IDO activity can be elicited and/or aggravated by inflammatory processes .
An elevated L-KYN level additionally provides a possibility to increase the concentration of QUIN, a
potent neurotoxic factor implicated in the pathogenesis of AD . Markedly increased serum levels of 3-
HK were reported in AD patients as compared with patients with major depression and a cognitive
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impairment. There were no significant differences between the groups in the levels of the other plasma
kynurenine  metabolites,  which  indicates  that  3-HK  produced  in  large  quantities  can  easily  be
transported across the BBB, resulting in a higher production of the downstream metabolite QUIN in
the brain of AD patients . Wu and co-workers demonstrated that the KP is overactivated by TDO-
mediated mechanisms in AD. In a triple transgenic mouse model of AD, the production of QUIN
proved to be strongly increased in the hippocampus, and TDO was highly expressed in the brain of
mice. Furthermore, significantly higher TDO and IDO-1 immunoreactivity and the co-localization of
TDO, QUIN, deposits of tau and amyloid protein were observed in the hippocampus of AD patients .
Nevertheless, the lack of an elevated central QUIN concentration in AD has also been described .
There is evidence that the L-KYN and 3-HK contents are slightly decreased in the frontal cortex,
caudate  nucleus,  putamen,  hippocampus  and  cerebellum,  while  the  concentrations  of  KYNA  are
significantly increased in the caudate nucleus and putamen in AD patients as compared with healthy
controls. Moreover, the levels of KYNA are moderately elevated in other brain areas, and significantly
higher reaction kinetics (Vmax and Km) and activities of KATs have been observed, correlating with
the level of KYNA in the striatal areas . 
Others have found significantly reduced KYNA levels in the serum, the erythrocytes and the CSF in
AD patients, but the concentration of L-KYN and the activity of the KATs remained unchanged . As
regards the relationship between the KP and CSF in dementia, a clinical study recently revealed a
gender difference between AD patients . Significantly higher KYNA levels in the CSF were detected
only in female AD patients, which suggest that this alteration is dependent on estrogen production.
The  concentration  of  KYNA  revealed  a  significant  association  between  phospho-tau  and  an
inflammation marker (soluble adhesion molecule-1) in the whole AD group. Correlations were not
detected from the aspect of the KYNA level and cognitive decline. These studies suggest that there is a
huge imbalance in the KP in the context of AD .  
A shift in the KP toward the formation of QUIN in the microglia can presumably contribute to the
development  of AD, which may be supplemented by the concomitant  presence of QUIN, Aβ and
inflammatory mediators.  These compounds are potent  generators of reactive oxygen species,  lipid
peroxidation  and  excessive  neurotoxic  glutamate  release.  Subsequently,  neuronal  death  and  tau
hyperphosphorylation can provoke the development of AD-specific changes . It is possible that the
marked increases in KYNA in the caudate nucleus and putamen may compensate the hyperactivity of
the striato-frontal loop in AD . The blockade of NMDA receptors by KYNA may be a response to the
neurotoxicity of QUIN, this mechanism being the only currently available therapeutic solution for the
treatment of AD by drugs such as the NMDA antagonist memantine . In the future, regulation of the
KP through enhancement the activities of TDO, IDO and KAT and/or reduction of the activity of
KMO as specific enzymes appear to be a possible target in the therapy of AD. However, the negative
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effects of high doses of KYNA on the cognitive functions, and especially its schizophrenia-inducing
features, cannot be ignored . 
It is worthwhile to look more closely at the two-sided  (Janus’s face) effects and properties of KYNA.
Rózsa and her co-workers demonstrated that KYNA can act as an agonist in a nanomolar doses, and as
an antagonist in a micromolar doses in an electrophysiological setup . Determination of the effective
neuroprotective  dose  of  KYNA  without  accompanying  undesired  side  effects  could  lead  to  an
alternative solution through which to diminishing the neurodegenerative and enhancing the cognitive
processes.
3. Kynurenines as possible therapeutical perspectives
The literature reveals that KYNA is definitely involved in neuroprotective mechanisms through its
inhibition of glutamate-induced excitotoxicity,  but its impact on cognitive performance is doubtful.
Although a detailed evaluation of the role of the KP in the pathogenesis of AD necessitates further
studies, we presume that a shift in the kynurenine metabolism toward neurotoxic compounds leads to a
relative KYNA deficiency.  This raises the possibility that  a well-controlled,  slight  increase in the
concentration of neuroprotective KYNA would be beneficial from a therapeutic aspect .
However, there are several counter-arguments to the systemic administration of KYNA: its solubility
is a limiting factor in higher doses, it is barely able to cross the BBB , and its clearance mediated by
organic anion transporters is rapid in the brain and the body . New and specific structural analogs of
KYNA have  been  designed  in  an  attempt  to  overcome  these  disadvantages  .  If  these  promising
neuroprotective agents could be endowed with enhanced water-solubility and BBB penetration, and if
their  application  in  appropriate  doses  not  accompanied  by  side-effects,  they  may  furnish  new
perspectives in the elimination of neurodegenerative processes . 
It  is interesting that there are natural sources of KYNA, such as  Gingko biloba ,  fresh vegetables
(broccoli, potatoes, carrots and cauliflower), and bee products (honey, propolis and bee pollen), which
contain approximately 1-10 nmol/g KYNA. Their  bio-absorption is presumably relatively low and
most of them contain higher KYNA content without heat-setting treatment , and they are frequent
components  of  the  daily  diet.  Experiments  have  been  conducted  to  determine  the  relevance  and
utilization  of  these  foods  in  the  human  organism.  Turski  and  co-workers  studied  the  absorption
processes of KYNA in the gastrointestinal system. When two doses of KYNA (25 mg/kg and 250
mg/kg) were administered to rats, and 5-100-fold or micromolar increases in KYNA concentration
were observed in the serum 120 minutes after the treatment. The liver and the kidneys exhibited 10-
fold elevated KYNA levels 30 minutes after the treatment .
An  in vitro study revealed that both acute and chronic administration of the anti-parkinsonian drug
zonisamide enhanced the release of L-KYN and KYNA in cultured astrocytes, whereas the level of
QUIN was unaltered. These alterations may influence the transmission in direct and indirect pathways
of basal  ganglia,  which indicates that  the release of neuroprotective kynurenine metabolites as an
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adjuvant mechanism can contribute to the effectiveness of monotherapy. It appears crucial to apply
combined or supplemented therapy in the treatment of PD and to develop drugs, which can indirectly
elevate the concentration of KYNA . As a therapeutic strategy, shifting the neurotoxic/neuroprotective
imbalance  toward  the  formation  of  KYNA or  a  reducing  of  the  level  of  QUIN may  come  into
consideration. 
Conclusions
Various factors contribute to the initiation and progression of AD, such as Aβ, tau, inflammation,
apoE, excitotoxicity, mitochondrial damage and oxidative stress. The astrocytes not only play the role
of structural and metabolic support for the neurons, but also form an interactive network with them,
providing  an  appropriate  microenvironment  for  their  normal  function,  and  influencing
neurotransmitter release and synaptic activity. In AD, the astrocytes have been shown to play a part in
excitotoxicity, amyloidogenesis and the chronic inflammation characteristic of the disease. One of the
first  events  to  occur  in  AD is  the  synaptic  dysfunction,  and  inflammatory  changes  linked to  the
astrocytes  may  ensue  even  before  the  typical  neurodegenerative  changes.  As  the  neurons  and
astrocytes are both deeply involved in the various phatogenic processes leading to AD. A medication
targeting only one component of this complicated network would therefore probably not work. Focus
should  be  placed  on  multi-target  approaches  to  the  therapy,  and  on  the  attainment  of  a  better
understanding of the role of the astrocytes in the disease course, which might offer new insight into the
pathomechanism  of  the  disease  and  new  therapeutic  targets.  In  view  of  the  part  played  by
excitotoxicity in the development of AD, the putative neuroprotective role of neuroactive kynurenines
in the therapy of AD should be further explored. 
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List of abbreviations
Aβ amyloid-beta
AAT aspartate aminotransferase
ACT α1-antichymotrypsin
AD Alzheimer’s disease
ADAM A-disintegrin and metalloproteinase genes
AICD amyloid precursor protein intracellular domain
Α-KG α-ketoglutarate
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor
AP-1 activated protein-1 transcription factor
ApoE apolipoprotein E
APC antigen-presenting cell
APC/C-Cdh1 anaphase-promoting complex/cyclosome (APC/C)–Cdh1
APP amyloid precursor protein
βAPP β amyloid precursor protein
AQP4 aquaporin 4
BACE β-site amyloid precursor protein cleaving enzyme
BBB blood-brain barrier
BDNF brain-derived growth factor
ChP choroid plexus
CoA acetyl coenzyme
CT computed tomography
CTFα C-terminal fragment α
CTFβ C-terminal fragment β
CTK cytokine
EAAT excitatory aminoacid transporters
GABA γ-aminobutyric acid
GDH glutamate dehydrogenase
GDNF glial-derived growth factor
GFAP glial fibrillary acidic protein
GLAST glutamate aspartate transporter
Gln glutamine
GLT-1 glutamate transporter-1
Glu glutamate
GluN2B glutamate-binding subunits 2B
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GS glutamine synthetase
GSK-3 glycogen synthase kinase
IDE insulin-degrading enzyme
IFNγ γ interferon
IL-6 interleukin-6
ILGF insulin-like growth factor
ISF interstitial fluid
LDLR low-density lipoprotein receptor
LRP low-density lipoprotein receptor-related protein
LTP long-term-potentiation
LTD long-term depression 
MMP-9 matrix metalloproteinase-9
MMSE Mini-Mental State Examination
MRI magnetic resonance imaging
α7nAChR α7 nicotinic acetylcholine receptor 
NEP neprilysin
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
NFT neurofibrillary tangles 
NMDA N-methyl-D-aspartate
NMDAR N-methyl-D-aspartate receptor
NO nitric oxide
NR nuclear receptor
NSAID non-steroidal anti-inflammatory medication
NVU neurovascular unit
OAA oxaloacetate
PAG phosphatase-activated glutaminase
PC pyruvate carboxylase
PET positron emission tomography
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase
PPAR peroxisomal proliferator-activated receptor
PSEN presenilin
PYR pyruvate
Rab GTPase Rab guanosine-5'-triphosphatase
RAGE receptor for advanced glycation end products 
S100β astroglial marker protein S100β
SAT1 system A transporter 1
SAT2 system A transporter 2
23
SN1 glutamine transporter, isoforms of system N
TCA tricarboxylic acid cycle
TGFβ transforming growth factor beta
TLR Toll-like receptor
TNFα tumor necrosis factor
VGLUT vesicular glutamate transporters
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Figure legends
Figure 1. Amyloid precursor protein processing
The image shows the non-amyloidogenic processing of APP through the action of α- and γ-secretases
leading soluble end products. The α-secretase cleaves APP to CTFα and the soluble αAPP, whereas γ-
secretase  cleaves  CTFα  to  AICD and  p3  peptide,  both  soluble.  In  the  amyloidogenic-processing
pathway,  β-secretase (BACE) cleaves APP to the membrane-bound CTFβ and to βAPP, the latter
located outside the cell. The γ-secretase cleaves CTFβ to the insoluble and neurotoxic Aβ with an
extracellular location and to AICD with an intracellular location.
Abbreviations: AICD: APP intracellular domain, APP: amyloid precursor protein, αAPP: α amyloid
precursor  protein,  βAPP:  β  amyloid  precursor  protein,  CTFα:  C-terminal  fragment  α,  CTFβ:  C-
terminal fragment β
Figure 2. Amyloid clearance
The  Rab  GTPase  family  members,  the  lysosomal  enzymes  and  neprilysin  play  a  role  in  the
intracellular clearance of amyloid. ApoE is the main chaperon of Aβ in the central nervous system. Aβ
is exported to the blood from the brain interstitial fluid through the BBB and a lesser extent through
the choroid plexus. The main carriers involved are the LRPs 1 and 2. Finally Aβ is eliminated in the
liver and a lesser extent in the kidney. 
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Abbreviations:  Aβ:  β  amyloid,  ApoE:  apolipoprotein  E,  BBB:  blood-brain  barrier,  ChP:  choroid
plexus, LRP 1,2: low-density lipoprotein receptor-related proteins
Figure 3. The functions of astrocytes
Astrocytes maintain fluid, ion and neurotransmitter homeostasis of the synaptic space. Water exchange
is regulated through the AQP4 receptors (arrow 1), whereas the excess K+ is taken up by the Kir 4.1 K+
channels (arrow 2) and released through gap junctions.  Astrocytes  release  arachidonic  acid,  nitric
oxide and prostaglandins and are able to regulate local CNS blood flow. Astrocytes take up excess
glutamate and prevent neurotoxic injury (arrow 3). Astrocytes take up Aβ through amyloid plaque
associated  proteins,  such  as  ApoE,  ApoJ  and  the  low-density  lipoprotein  receptor  (arrow  4).
Astrocytes  degrade  amyloid  through  neprilysin  and  matrix  metalloproteinases  (arrow  5).
Overexpression of BACE and amyloid products occur in the activated astrocytes (arrow 6). Astrocytes
dispose the Aβ into the blood through the BBB (arrow 7) and also through the paravenous spaces
(arrow 8). 
Abbreviations: Aβ: β amyloid, AA: arachidonic acid, ApoE: apolipoprotein E, ApoJ: apolipoprotein J,
APP: amyloid precursor protein, AQP4: aquaporin 4, BACE: β-site amyloid precursor protein cleaving
enzyme, EAAT: excitatory amino acid transporter, GLU: glutamate, LDLR: low-density lipoprotein
receptor, MMP: matrix metalloproteinase, NEP: neprilysin, NO: nitric oxide, PG: prostaglandins 
Figure 4. Activated astrocytes in the pathomechanism of AD.
Activated astrocytes release inflammatory mediators and maintain a chronic inflammatory state. The
release of nitric oxide and reactive oxygen species causes oxidative stress. The overexpression of
BACE occurs in activated astrocytes and leads to further amyloidogenesis. The overexpression of α1-
antichymotrypsin  might  induce  tau  hyperphosphorylation  and  inhibit  Aβ  breakdown.  Astrocyte
activation is marked by the upregulation of glial fibrillary acidic protein and S100β protein.
Abbreviations:  Aβ: β amyloid,  ACT: α1-antichymotrypsin,  CTK: cytokines,  GFAP:  glial  fibrillary
acidic  protein,  IFNγ:  γ  interferon,  IL1β:  β1  interleukin,  NO:  nitric  oxide,  ROS:  reactive  oxygen
species, S100β: astroglial marker protein S100β, TNFα: tumor necrosis factor α.
Figure 5. The role of astrocytes in glutamate metabolism and excitotoxicity. 
In  astrocytes,  glucose  is  glycolytically  transformed  into  pyruvate.  Pyruvate  is  degraded  to  acetyl
coenzyme that condenses with oxaloacetate to form citrate, which is a component of the tricarboxylic
acid cycle.  During one cycle, citrate is transformed into oxaloacetate, which condenses again with
acetyl-CoA for energy production. Pyruvate carboxylase converts pyruvate to  de novo oxaloacetate.
This enzyme is present in astrocytes, but absent in neurons. Two molecules of pyruvate form a  de
novo molecule of citric acid. Through the production of  de novo citrate molecules, α-ketoglutarate
becomes available for glutamate synthesis. In the astrocytes glutamate is converted to glutamine by
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glutamine synthetase. Glutamine is released from astrocytes through the SN1 transporter. From the
extracellular  space glutamine enters the neurons through the SAT1 and SAT2 transporters.  In the
neurons glutamine is converted to glutamate, which returns to vesicles via the vesicular glutamate
transporters. A small amount of neurotransmitters are released by neurons and returned by reuptake
(discontinuous  arrow),  but  the  majority  enters  the  astrocyte  through  the  glutamate  transporters
(continuous  thick  arrow).  Consequently  astrocytes  maintain  low  levels  of  glutamate  in  the
extracellular space and might prevent excitotoxic neuronal injury. In AD the deposition of Aβ affects
the  glutamatergic  vesicular  pool,  which  might  cause  decreases  in  the  expression  of  the  vesicular
glutamate transporters and exerts its neurotoxic effects mainly on the NMDARs resulting synaptic
dysfunction  (thin  dotted  arrow).  Aβ  deposition  decreases  astrocytic  glutamate  uptake  by  the
downregulation of EAATs and impairs the metabolism of astrocytes. CTKs downregulate EAATs and
reduce  the  expression  of  glutamine  synthetase  (thick  dotted  arrow).  The  result  is  a  diminished
glutamate  uptake to  astrocytes  and a reduced glutamine  release from astrocytes  that  impairs  their
ability to protect neurons from excitotoxic injury. 
Abbreviations: Aβ: amyloid β, AAT: aspartate aminotransferase, CIT: citrate, CoA: acetyl coenzyme,
CTK:  cytokines,  EAAT1,  2:  excitatory  amino  acid  transporter  1  and  2,  GDH:  glutamate
dehydrogenase,  Gln:  glutamine,  Glu:  glutamate,  GS:  glutamine  synthetase,  αKG:  α-ketoglutarate,
NMDAR:  N  methyl-D  aspartate  receptor,  OAA:  oxaloacetate,  PC:  pyruvate  carboxylase,  PYR:
pyruvate, SAT1, 2: system A transporter 1 and 2, SN1: glutamine transporter, isoforms of system N,
TCA: tricarboxylic acid cycle, VGLU: vesicular glutamate transporters.
Figure. 6. Neuroprotective and neurotoxic pathways of kynurenines 
Most of the TRP may convert to N-fKYN in the plasma by special enzymes TDO and/or IDO-1, IDO-
2.  L-KYN is  synthesized  in  the  brain  and serves  as  a  key molecule  between  the  neurotoxic  and
neuroprotective directions of the pathway. QUIN, a neurotoxic compound is produced from L-KYN in
the microglia cells,  catalyzed by KMO, via additional toxic metabolites (3-HK and 3-HA). These
agents  can  generate  toxic  free  radicals,  oxidative  stress,  lipid  peroxidation  and  glutamate
excitotoxicity. Subsequently it contributes to the development of neurodegeneration and dementia. In
contrast,  the  characteristically  neuroprotective  KYNA  is  formed  directly  from  L-KYN  in  the
astrocytes, catalyzed by KATs. KYNA is an endogenous inhibitor of the glutamate release, thereby it
has neuroprotective, antinociceptive, anti-inflammatory effects and influences the cognitive functions.
Abbreviations:  3-HA: 3-hydroxyanthranillic acid, 3-HK: 3-hydroxykynurenine, IDO-1: indoleamine
2,3-dioxygenase  1,  IDO-2:  indoleamine  2,3-dioxygenase  2,  KATs:  kynurenine  aminotransferases,
KMO: kynurenine 3-monooxygenase, KYNA: kynurenic acid, L-KYN: L-kynurenine, N-fKYN: N-
formylkynurenine, QUIN: quinolinic acid, TDO: tryptophan 2,3-dioxygenase, TRP: tryptophan
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